Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Sayegh

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Urologic Oncology|August 2, 2022
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinomaNishita Tripathi, Yeonjung Jo, Abhishek Tripathi, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
Clinical Genitourinary Cancer|May 2, 2026
Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell CarcinomaWadih Issa, Nicolas Sayegh, Damla Gunenc, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
European Urology Oncology|May 12, 2024
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized TherapyVinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, et al.
JCO Precision Oncology|May 23, 2024
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMIVinay Mathew Thomas, Beverly Chigarira, Georges Gebrael, et al.
Clinical Genitourinary Cancer|December 12, 2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint InhibitorsNeal S Chawla, Nicolas Sayegh, Nishita Tripathi, et al.
JAMA Network Open|May 2, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USVinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Urologic Oncology|August 2, 2022
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinomaNishita Tripathi, Yeonjung Jo, Abhishek Tripathi, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
Clinical Genitourinary Cancer|May 2, 2026
Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell CarcinomaWadih Issa, Nicolas Sayegh, Damla Gunenc, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
European Urology Oncology|May 12, 2024
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized TherapyVinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, et al.
JCO Precision Oncology|May 23, 2024
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMIVinay Mathew Thomas, Beverly Chigarira, Georges Gebrael, et al.
Clinical Genitourinary Cancer|December 12, 2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint InhibitorsNeal S Chawla, Nicolas Sayegh, Nishita Tripathi, et al.
JAMA Network Open|May 2, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the USVinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
Pageof 8